Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Alessandro Cerri, Oliver Fairhurst and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Simone Lorenzi and Asude Sena Moya.
Search results for biogen insufficiency
VEGF Trap Eye Trapped by Genentech Patent - Regeneron & Bayer unsuccessful VEGF Trap Eye Trapped by Genentech Patent - Regeneron & Bayer unsuccessful Reviewed by Darren Smyth on Thursday, March 29, 2012 Rating: 5
A case for our times: Ambiguity, insufficiency and uncertainty (Anan Kasei v Neo [2019] EWCA Civ 1646) A case for our times: Ambiguity, insufficiency and uncertainty (Anan Kasei v Neo [2019] EWCA Civ 1646) Reviewed by Dr Rose Hughes on Friday, November 01, 2019 Rating: 5
Implausibly incredible or just plain insufficient? Implausibly incredible or just plain insufficient? Reviewed by Stephen on Wednesday, May 31, 2017 Rating: 5
More than the patentee deserves? No problem ... More than the patentee deserves? No problem ... Reviewed by Jeremy on Thursday, April 10, 2008 Rating: 5
Biotech patent case law: why is it different, idiosyncratic and always changing? Biotech patent case law: why is it different, idiosyncratic and always changing? Reviewed by Suleman Ali on Sunday, January 18, 2015 Rating: 5
Biogen, Lundbeck, Lord Hoffmann and a tour de force Biogen, Lundbeck, Lord Hoffmann and a tour de force Reviewed by Jeremy on Wednesday, February 25, 2009 Rating: 5
FibroGen v. Akebia: Arnold LJ addresses insufficiency, equivalence, second medical use claims, and much more FibroGen v. Akebia: Arnold LJ addresses insufficiency, equivalence, second medical use claims, and much more Reviewed by Léon Dijkman on Saturday, April 25, 2020 Rating: 5
The Itch That Couldn't Be Scratched: Merial lose appeal in Omnipharm "flea patent" dispute The Itch That Couldn't Be Scratched: Merial lose appeal in Omnipharm "flea patent" dispute Reviewed by Annsley Merelle Ward on Wednesday, January 23, 2013 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.